Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
December 14, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
Bioxytran Interview at the Emerging Growth Conference
December 12, 2022 09:45 ET
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
December 08, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics
November 22, 2022 08:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet...
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
October 25, 2022 07:00 ET
|
BIOXYTRAN, INC.
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON,...
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
August 01, 2022 09:00 ET
|
BIOXYTRAN, INC.
ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology...